<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608110</url>
  </required_header>
  <id_info>
    <org_study_id>418-102-00001</org_study_id>
    <nct_id>NCT04608110</nct_id>
  </id_info>
  <brief_title>A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Study to Evaluate the Pharmacokinetics of ASTX030 in Patients With Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify the doses of the azacitidine (AZA) tablets and&#xD;
      cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA&#xD;
      injection at 75 mg/m2&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• AUC ratio of AZA after oral administration of AZA tablets in combination with CED tablets compared with subcutaneous (SC) administration of AZA injection</measure>
    <time_frame>Up to 1 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>Azacitidine + Cedazuridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Azacitidine Tablets for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration&#xD;
Drug: Cedazuridine Tablets for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX030</intervention_name>
    <description>In Cycle 1 (28 days per cycle), single dose oral azacitidine will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine and oral cedazuridine on day 2-7; in Cycle 2 and onward, oral azacitidine and oral cedazuridine will be administered on day 1-7</description>
    <arm_group_label>Azacitidine + Cedazuridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 20 years or older&#xD;
&#xD;
          -  Patients with a diagnosis of MDS (refractory anemia [RA], refractory anemia with&#xD;
             ringed sideroblasts [RARS], refractory anemia with excess blasts [RAEB], refractory&#xD;
             anemia with excess blasts in transformation [RAEB-T], or chronic myelomonocytic&#xD;
             leukemia [CMML]) according to the French-American-British (FAB) classification&#xD;
             Low-risk patients who fall under the risk category of low or intermediate-1 (Int-1)&#xD;
             based on the International Prognostic Scoring System (IPSS) can be enrolled only if&#xD;
             they are unlikely to respond to any other treatment or if they are currently being&#xD;
             treated with azacytidine (AZA) injection&#xD;
&#xD;
          -  Patients with an ECOG PS score of 0 or 1 or with an ECOG PS score of 2 due to primary&#xD;
             disease-associated conditions&#xD;
&#xD;
          -  Patients with adequate organ function as indicated below&#xD;
&#xD;
               1. Hepatic function: All of the following criteria must be satisfied.&#xD;
&#xD;
                    -  Total bilirubin ≤ 2.0 × upper limit of normal (ULN)&#xD;
&#xD;
                    -  Aspartate aminotransferase (AST) ≤ 2.5 × ULN&#xD;
&#xD;
                    -  Alanine aminotransferase (ALT) ≤ 2.5 × ULN&#xD;
&#xD;
               2. Renal function: Either of the following criteria must be satisfied.&#xD;
&#xD;
                    -  Serum creatinine ≤ 1.5 × ULN&#xD;
&#xD;
                    -  Creatinine clearance or glomerular filtration rate ≥ 50 mL/min&#xD;
&#xD;
               3. Respiratory function: percutaneous arterial oxygen saturation (SpO2) ≥ 90%&#xD;
&#xD;
          -  Patients who are expected to survive for at least 3 months&#xD;
&#xD;
          -  Patients who give written consent to participate in the trial using the informed&#xD;
             consent form approved by the institutional review board&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unlikely to respond to AZA&#xD;
&#xD;
          -  Patients who have received chemotherapy, hormone therapy, antibody therapy,&#xD;
             radiotherapy, or other exploratory anti-cancer treatments for the primary disease&#xD;
             within 3 weeks prior to the first administration of the investigational medicinal&#xD;
             product (IMP)&#xD;
&#xD;
          -  Patients who have used any other IMP or any privately imported medicine within 4 weeks&#xD;
             prior to the first administration of IMP&#xD;
&#xD;
          -  Patients with heart disease of Class 3 or 4 according to the New York Heart&#xD;
             Association classification&#xD;
&#xD;
          -  Patients with uncontrolled systemic disease or active infection&#xD;
&#xD;
          -  Patients with uncontrolled gastric or duodenal ulcer&#xD;
&#xD;
          -  Patients with prior or current interstitial lung disease&#xD;
&#xD;
          -  Patients with a history of surgical gastrectomy&#xD;
&#xD;
          -  Patients with life-threatening conditions/symptoms, multiple organ failure, or other&#xD;
             factors (including laboratory abnormalities) that, in the opinion of the investigator,&#xD;
             are likely to affect their safety or the absorption and metabolism of AZA and&#xD;
             cedazuridine (CED), or influence the trial evaluation&#xD;
&#xD;
          -  Patients with other malignancies (except appropriately treated basal cell carcinoma,&#xD;
             squamous cell carcinoma, or cervical carcinoma in situ; prostate or breast cancer&#xD;
             stabilized by endocrine therapies; and malignancies that have not relapsed for at&#xD;
             least 1 year since the last successful treatment)&#xD;
&#xD;
          -  Patients who are positive for HIV antibody, HBV-DNA, or HCV antibody&#xD;
&#xD;
          -  Patients with any ≥ Grade 2 AE (except alopecia) associated with prior treatment of&#xD;
             the primary disease. However, the parameters defined in inclusion criterion above are&#xD;
             excluded.&#xD;
&#xD;
          -  Patients who have undergone a highly invasive and extensive surgical procedure within&#xD;
             4 weeks prior to the first administration of IMP&#xD;
&#xD;
          -  Patients who previously underwent or plan on undergoing hematopoietic stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  Patients with a history of hypersensitivity to the active ingredient or any excipient&#xD;
             of IMP&#xD;
&#xD;
          -  Patients who are, in the opinion of the investigator, at high risk for being unable to&#xD;
             comply with the trial protocol because of mental disorders or other medical conditions&#xD;
             (alcohol/substance abuse or addiction)&#xD;
&#xD;
          -  Pregnant or nursing female patients, or female patients with a positive pregnancy test&#xD;
             at screening. Nursing patients cannot participate in the trial even if they&#xD;
             discontinue breastfeeding. Female patients must undergo a pregnancy test to confirm&#xD;
             that they are not pregnant at screening. However, a pregnancy test is not necessary&#xD;
             for female patients without childbearing potential (ie, patients with a history of&#xD;
             bilateral oophorectomy or hysterectomy or who have been postmenopausal for at least 12&#xD;
             months except for cases where menopause could be due to the effect of antineoplastic&#xD;
             treatment).&#xD;
&#xD;
          -  Sexually active males (except those with a history of bilateral orchiectomy) or&#xD;
             females of childbearing potential who do not agree to practice 2 different methods of&#xD;
             birth control or remain abstinent during the trial and for 3 months (males) and 6&#xD;
             months (females) after the last dose of IMP. If birth control is employed, 2 of the&#xD;
             following precautions must be used: vasectomy, tubal ligation, intrauterine device,&#xD;
             oral contraceptive, and condom (all methods approved or certified in Japan)&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, are otherwise ineligible to&#xD;
             participate in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junji Ikeda, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Yamagata University Hospital</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

